Recursion Pharmaceuticals, Inc. has announced the dosing of the first patient in a Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule aimed at treating recurrent Clostridioides difficile (C. diff) infection. REC-3964 is the first new chemical entity developed by Recursion using their proprietary RecursionOS platform.
REC-3964 employs a novel, non-antibiotic approach with a unique mechanism of action. It works by binding and blocking the catalytic activity of the toxin's innate glucosyltransferase, thereby inhibiting the toxin produced by C. diff in the gastrointestinal tract. This innovative strategy represents a significant advancement in the treatment of recurrent C. diff infections, which affect up to 175,000 individuals each year in the U.S. and result in more than 29,000 deaths annually.
The initiation of this Phase 2 study is a critical milestone in the development of REC-3964, offering hope for a new treatment option for patients suffering from this challenging condition.
